Follow on Google News News By Tag Industry News News By Place Country(s) Industry News
Follow on Google News | The World Prostate Therapeutics Market will reach $8.3bn in 2015 predicts new visiongain reportBy: Visiongain A new report by visiongain predicts that the world prostate cancer therapeutics market will reach $8.3bn in 2015. This forecast and others appear in The Prostate Cancer Therapeutics Market Forecast 2015-2025: Opportunities For Leading Companies, published in August 2015. Visiongain is a business information provider based in London, UK. Prostate cancer, also called carcinoma of the prostate, is a form of cancer which originates in the prostate; a walnut-shaped gland in the male reproductive system. The disease possesses the metastatic ability to spread into the bones, lymph nodes, rectum, bladder and the lower part of the ureter. However, the rate of growth tends to be very slow compared to other cancers and research indicates that many older men develop at least a microscopic evidence of prostate cancer. The continuously increasing prevalence of the disease, driven by a wider use of screening, makes the prostate cancer market an auspicious environment for companies willing to introduce innovative therapeutic solutions to a number of unmet medical needs. Maria Kercheva, a pharmaceutical and medical devices industry analyst in visiongain, said:“In 2012, prostate cancer affected 1.1 million people and caused the deaths of 307,000 men worldwide. Those figures, combined with the significant medical needs that remain unmet, increasing use of screening worldwide and rising patient awareness speak for the potential of the market as a whole. A strong pipeline of investigational compounds discussed in this report will undoubtedly change the prostate cancer drugs landscape. Additionally, opportunities for medical devices companies continue arising, as patients demand better diagnostics. The next decade will see advances in both segments and will create opportunities for companies to establish themselves in the therapeutics market. Visiongain’s report provides revenue forecasts until 2025 for the world prostate cancer therapeutics market and leading drugs. Furthermore, the report discusses a number of compounds that are currently undergoing clinical development. Several promising agents in late-stage development, including Johnson & Johnson’s ARN-509, will serve as long- term growth drivers. Additionally, the report offers comprehensive analyses of seven leading pharmaceutical companies, their strategies and financial performances. A detailed national market forecast to 2025 provides a global outlook, as well as individual forecasts for each region. Interviews with key experts offer an insight into the current industrial trends, challenges and opportunities. Finally, the report includes a SWOT analysis, as well as a Porter’s five forces analysis, to study the level of competition and maximise the value of your business. The Prostate Cancer Therapeutics Market 2015-2025: Opportunities for Leading Companies adds to visiongain’s range of analytical reports on industries and markets in healthcare. For an executive summary please contact: Email: Sara Peerun on sara.peerun@ Tel: +44 (0) 20 7336 6100 Notes for Editors If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@ About visiongain Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. From its head office in London, UK, visiongain produces a range of newsletters, business reports and e-zines covering current affairs and market trends in the Energy, Telecoms, Pharmaceutical, Defence, and Materials sectors. Visiongain publishes reports produced by its in-house analysts, who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high quality, original analyses to inform their strategic decisions. End
Account Phone Number Disclaimer Report Abuse
|
|